Executive Management Team
Our leadership team creates, hones and maintains our company’s focus and commitment to excellence in everything we do. The tireless work of these individuals continues to drive our growth, success and shareholder value.
Learn more about the dynamic people leading the way for Anika Therapeutics.
Charles H. Sherwood, Ph.D.
President and Chief Executive Officer
Charles H. Sherwood, Ph.D. has been President and Chief Executive Officer of Anika Therapeutics since 2002. Dr. Sherwood joined Anika in 1998 with extensive experience in research, engineering, manufacturing, quality assurance, regulatory affairs and business management. He first served at Anika in the position of Vice President of Research, Development and Engineering.
Prior to joining Anika, he was a senior director with Chiron Vision, responsible for medical product development and commercialization. From 1982 to 1995, Dr. Sherwood was with IOLAB Corporation, a division of Johnson & Johnson, where he led the Research and Product Development organization. Earlier, he held various technical and management positions with Hughes Aircraft Company and Lord Corporation. He was also on the faculty of California State Polytechnic University, Pomona.
Dr. Sherwood holds a doctorate and master’s degree in polymer science and engineering from the University of Massachusetts, a bachelor’s degree in chemical engineering from Cornell University and a certificate in management from Claremont Graduate School.
Chief Financial Officer
On April 1, 2013, Sylvia Cheung was appointed as Chief Financial Officer. Ms. Cheung brings to Anika a substantial number of years of financial and general management experience. Prior to her current position, Sylvia was the Vice President of Strategic Processes; and previously, she served as the General Manager for the company’s Italian-based subsidiary, Anika S.r.l. She joined Anika as Controller in 2005. In addition to fulfilling wide-ranging financial responsibilities as Controller, Sylvia led the company’s integration of Anika S.r.l. subsequent to its acquisition in 2009.
Prior to Anika, she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc. From 1995 to 2000, Sylvia worked for PricewaterhouseCoopers, LLP as an Audit Senior Associate.
Sylvia holds a bachelor of business administration degree in accounting from the University of Massachusetts in Amherst, a master’s degree in business administration from Boston University, and is a Certified Public Accountant (inactive).
Chief Commercial Officer
Richard Hague joined Anika Therapeutics, Inc. as Chief Commercial Officer on October 26, 2015. Most recently, Richard served as Vice President, Sales and Marketing, for TEI Medical, where he was responsible for driving revenue growth, building the sales and marketing teams, and implementing strategies to drive national account and federal and private payer acceptance of the company’s technology platform. He previously was Vice President, Sales, Marketing and Commercial Operations at Sanofi Biosurgery, where he led the build out of the global sales and marketing team and oversaw all commercial activities in the U.S. for the company’s Cell Therapy and Regenerative Medicine business. Richard’s prior experience also includes leadership positions at Genzyme Biosurgery as Senior Director and Head of U.S. Sales, and Northeast Regional Sales Director.
Richard holds a B.S. in Marketing from the University of Connecticut.
Chief Operations Officer
Dana Alexander joined Anika Therapeutics, Inc. as its Chief Operations Officer on April 4, 2016. Prior to joining Anika, Dana spent the previous 14 years in various leadership roles at Genzyme Corporation. Most recently, Mr. Alexander served as Senior Director of Biologics Manufacturing Operations, where he headed manufacturing at Genzyme’s flagship biologics plant including overseeing production planning and execution, bringing new manufacturing capacity on-line, and implementing new production and quality systems. During his tenure at Genzyme, Mr. Alexander provided operational oversight for the construction, start-up, and approval of a new cGMP cell culture facility, managed Chemistry, Manufacturing, and Control (CMC) activities for a variety of late stage and commercial products, and led operation product teams across complex supply chains to deliver global clinical and commercial supply requirements.
Dana holds a Master’s in Business Administration from Boston University, and a Bachelor of Science in Chemical Engineering from Northeastern University.
Edward Ahn, Ph.D.
Chief Technology and Strategy Officer
Edward Ahn, Ph.D., joined Anika Therapeutics, Inc. as Chief Technology and Strategy Officer on October 30, 2014. Most recently, Dr. Ahn was Managing Director and Chief Science Officer at MedCap Advisors where he built merger strategies, strategic partnerships and licensing agreements for emerging medical device, biotechnology and biological organizations with a focus on regenerative medicine. Prior to his work at MedCap, Dr. Ahn was Vice President of Product Development for Pioneer Surgical Biologics. In this role Dr. Ahn directed Pioneer Surgical Biologic’s product development policies, objectives and initiatives. He has also served as Chief Executive Officer, Chief Technology Officer and Founder of Angstrom Medica, Inc., a company based upon his doctoral thesis work and focused on commercializing nanotechnology in the area of Orthopedics.
Dr. Ahn holds a B.S. in Chemical Engineering from Stanford University and M.S. (Chemical Engineering Practice) and Ph.D. in Chemical Engineering from Massachusetts Institute of Technology.
Vice President of Marketing
Jean Bjerke joined Anika Therapeutics, Inc. as Vice President of Marketing on March 21, 2016. Prior to joining Anika, Ms. Bjerke spent 15 years specializing in marketing with the orthopedic device segments for Smith & Nephew and DePuy Orthopedics. Most recently, Ms. Bjerke was the Global Senior Director, Marketing and Development, for Smith & Nephew where she was responsible for leading both the upstream and downstream marketing activities for the shoulder reconstruction franchise. Her responsibilities included developing and implementing the global marketing strategy and working closely with the international and regional marketing managers to commercialize the product and gain market share. Prior to this role, Ms. Bjerke held director-level roles in marketing education and grant programs, and product marketing for a number of years at DePuy Orthopedics, a Johnson and Johnson company.
Ms. Bjerke holds a Master’s Degree in Business Administration, with a marketing concentration, from St. Louis University, and a Bachelor of Science Degree in Marketing, with a minor in economics, from Eastern Illinois University.
Vice President of Human Resources
On March 24, 2014, Steven Cyr joined Anika Therapeutics Inc. as the Vice President of Human Resources. He is responsible for all of the global human capital activities and programs of the company. Steve comes to Anika from DENTSPLY International, formerly Astra Tech Inc.(Astra Zeneca) in Waltham, MA where he worked from 2006 to 2014. Steve served as Vice President, Human Resources DENTSPLY Implants Division (North America). He was responsible for leading and managing all aspects of HR for the Dental Implant and Urology divisions. The employee population included sales, marketing, operations, R&D, manufacturing, and G&A. Previously, Steve was employed by Sepracor Pharmaceuticals in Marlborough, MA as the Associate Director Human Resources, Client Services. In addition, he has worked as a consultant supporting HR initiatives at Monster Worldwide in Maynard and DePuy AcroMed Medical Devices in Raynham. Furthermore, he has held positions with StorageNetworks, Inc., The Avicon Group, Inc., i2 Technologies, Cambridge Technology Partners, TASC, and Wang Information Services Corp.
Steve has a B.S. from the University of Maine in Liberal Arts Psychology (Honors), and an M.A. in Industrial /Organizational Psychology (Honors) from the University of New Haven.